미국의 의료 데이터 수익화 시장(품질, 치료 성과, 지불 정보 분야) 규모, 점유율, 동향 분석 보고서 : 조직별, 제품 유형별, 구매자별, 구매자 대 제품 유형별 및 부문별 예측(2026-2033년)

U.S. Healthcare Data Monetization Market For Quality, Outcomes & Payment Intelligence Summary

The U.S. healthcare data monetization market size for quality, outcomes & payment intelligence (serviceable obtainable market) was estimated at USD 955.44 million in 2025 and is projected to reach USD 1,705.53 million by 2033, growing at a CAGR of 7.77% from 2026 to 2033. This growth is driven by the rapid expansion of healthcare data volume (EHR, Claims, Wearables), rising demand for Real-World Data (RWD) & Real-World Evidence (RWE), increasing adoption of AI, advanced analytics & cloud platforms, and growing payer focus on cost optimization & risk management.

The U.S. healthcare ecosystem generates massive datasets through widespread adoption of electronic health records (EHRs), imaging systems, claims databases, and connected devices. This exponential growth in structured and unstructured data creates a large monetizable asset base, enabling providers and payers to commercialize de-identified datasets and insights.

Moreover, there is a significant shift in the U.S. life sciences ecosystem toward leveraging real-world data (RWD) and generating real-world evidence (RWE) to complement traditional clinical trial data. Pharmaceutical and biotechnology companies are increasingly utilizing these datasets to optimize clinical trial design, identify eligible patient populations, monitor treatment outcomes, and support regulatory submissions.

In addition, regulators and payers are placing greater emphasis on post-market evidence to assess drug efficacy and cost-effectiveness in real-world settings. This growing reliance on RWD/RWE has created a strong demand for high-quality, longitudinal patient datasets, encouraging healthcare providers and data aggregators to monetize their data assets through partnerships, licensing agreements, and analytics services. As a result, data monetization is becoming deeply embedded in the broader drug development and commercialization lifecycle.

U.S. Healthcare Data Monetization Market Report Segmentation

This report forecasts revenue growth analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. healthcare data monetization market for quality, outcomes & payment intelligence report based on entity, product type, buyer type, and buyer vs product sub-segmentation:

• Entity Outlook (TAM, SAM & SOM, USD Million, 2021 - 2033)
• Healthcare entities
• Non-healthcare entities
• Healthcare Entities Outlook (SAM & SOM, USD Million, 2021 - 2033)
• By Product Type
  • Data Subscription (patient-level / aggregate / licensed datasets)
  • Insights-as-a-Service (curated analytics products)
  • Models / Decision Engines (AI-enabled predictive products)
• By Buyer Type
  • Pharmaceutical Companies
  • Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
  • HCP & Customer Targeting (Physician targeting, segmentation, sales enablement)
  • Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
  • Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
  • Health Systems & Providers
  • Go-to-Market & Contracting (Value-based care enablement, service line optimization)
  • Quality & Care Gap Closure (HEDIS, Stars, performance improvement)
  • Network & Operational Optimization (Referral management, capacity optimization, leakage reduction)
  • Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
  • Retail Pharmacies
  • Independent Pharmacies
  • Chain Pharmacies
  • Other Non-Payer Healthcare Entities
• Buyer vs Product Type Sub-Segmentation Outlook (SAM & SOM, USD Million, 2021 - 2033)
• Pharmaceutical Companies
  • Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
  • Data subscription (clinical + claims + quality datasets)
  • Insights service (trial feasibility analytics)
  • Model/engines (site selection AI tools)
  • HCP & Customer Targeting (Physician targeting, segmentation, sales enablement)
  • Data (HCP-level claims + quality signals)
  • Insights (targeting analytics)
  • Models (real-time targeting engines)
  • Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
  • Data (payer + quality + reimbursement datasets)
  • Insights (access analytics)
  • Models (pricing / access optimization tools)
  • Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
  • Data (payer + quality + reimbursement datasets)
  • Insights (access analytics)
  • Models (pricing / access optimization tools)
• Health Systems & Providers
  • Data (EMR + claims + quality data)
  • Insights (care gap + operational analytics)
  • Models (VBC optimization engines)
• Retail Pharmacies
  • Data (patient + prescription + adherence signals)
  • Insights (patient behavior / refill optimization)
  • Models (adherence / engagement engines)
• Other Non-Payer Healthcare Entities
  • Data packages
  • Insights platforms
  • API / embedded models

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
  • 1.3.5. Details of Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Methodology Architecture Overview
  • 1.5.1. Modeling framework
    • 1.5.1.1. Serviceable Obtainable Market (SOM) Analysis - Approach/Assumptions
      • 1.5.1.1.1. Commodity Flow Analysis
      • 1.5.1.1.2. Scenario-Based Penetration Modeling (2021 - 2033)
      • 1.5.1.1.3. Interpretation of the Penetration Model
    • 1.5.1.2. Total Addressable Market (TAM) Analysis - Approach/Assumptions
      • 1.5.1.2.1. Bottom-up estimation logic
      • 1.5.1.2.2. Top-down validation logic
      • 1.5.1.2.3. Triangulation framework
    • 1.5.1.3. QFD-Based Methodology for SOM Share Allocation
      • 1.5.1.3.1. Scenario-based SOM share allocation
• 1.6. List of Secondary Sources
• 1.7. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market attractiveness snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot
• 2.4. Top 3 monetization pathways
• 2.5. Priority use cases
• 2.6. Key risks (regulatory + channel conflict)

Chapter 3. Market Variables, Trends, and Scope

• 3.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market - Market Dynamics
  • 3.1.1. Market Driver Analysis
  • 3.1.2. Market Restraint Analysis
  • 3.1.3. Market Opportunity Analysis
  • 3.1.4. Market Challenge Analysis
• 3.2. Business Environmental Tools Analysis: U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market
  • 3.2.1. Porter's Five Forces Analysis
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTLE Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic and Social landscape
    • 3.2.2.3. Technological landscape
    • 3.2.2.4. Environmental landscape
    • 3.2.2.5. Legal Landscape

Chapter 4. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: By Entity TAM, SAM & SOM Estimates & Trend Analysis

• 4.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity: Key Takeaways
• 4.2. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market: Entity Movement & Market Share Analysis, 2025 & 2033
• 4.3. Healthcare entities
  • 4.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Product Type
    • 4.3.2.1. Data Subscription (patient-level / aggregate / licensed datasets)
      • 4.3.2.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.2. Insights-as-a-Service (curated analytics products)
      • 4.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.3. Models / Decision Engines (AI-enabled predictive products)
      • 4.3.2.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Buyer Type
    • 4.3.3.1. Pharmaceutical Companies
      • 4.3.3.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.1.2. Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
        • 4.3.3.1.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.1.3. HCP & Customer Targeting (Physician targeting, segmentation, sales enablement)
        • 4.3.3.1.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.1.4. Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
        • 4.3.3.1.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.1.5. Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
        • 4.3.3.1.5.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.2. Health Systems & Providers
      • 4.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.2. Go-to-Market & Contracting (Value-based care enablement, service line optimization)
        • 4.3.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.3. Quality & Care Gap Closure (HEDIS, Stars, performance improvement)
        • 4.3.3.2.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.4. Network & Operational Optimization (Referral management, capacity optimization, leakage reduction)
        • 4.3.3.2.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.5. Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
        • 4.3.3.2.5.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.3. Retail Pharmacies
      • 4.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.3.2. Independent Pharmacies
        • 4.3.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.3.3. Chain Pharmacies
        • 4.3.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.4. Other Non-Payer Healthcare Entities
      • 4.3.3.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Non-healthcare entities
  • 4.4.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer vs Product Type Sub-Segmentation SAM & SOM Estimates & Trend Analysis

• 5.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer vs Sub-Segmentation: Key Takeaways
• 5.2. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market: Buyer X Sub-Segmentation Movement & Market Share Analysis, 2025 & 2033
• 5.3. Pharmaceutical Companies
  • 5.3.1. Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
    • 5.3.1.1. Data subscription (clinical + claims + quality datasets)
      • 5.3.1.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.1.2. Insights service (trial feasibility analytics)
      • 5.3.1.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.1.3. Model/engines (site selection AI tools)
      • 5.3.1.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.2. Health Systems & Providers
    • 5.3.2.1. Data (HCP-level claims + quality signals)
      • 5.3.2.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.2.2. Insights (targeting analytics)
      • 5.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.2.3. Models (real-time targeting engines)
      • 5.3.2.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.3. Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
    • 5.3.3.1. Data (payer + quality + reimbursement datasets)
      • 5.3.3.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.3.2. Insights (access analytics)
      • 5.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.3.3. Models (pricing / access optimization tools)
      • 5.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.4. Formulary Analytics/Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
    • 5.3.4.1. Data (payer + quality + reimbursement datasets)
      • 5.3.4.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.4.2. Insights (access analytics)
      • 5.3.4.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.4.3. Models (pricing / access optimization tools)
      • 5.3.4.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Health Systems & Providers
  • 5.4.1. Data (EMR + claims + quality data)
    • 5.4.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Insights (care gap + operational analytics)
    • 5.4.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Models (VBC optimization engines)
    • 5.4.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Data (patient + prescription + adherence signals)
    • 5.5.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Insights (patient behavior / refill optimization)
    • 5.5.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Models (adherence / engagement engines)
    • 5.5.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Other Non-Payer Healthcare Entities
  • 5.6.1. Data packages
    • 5.6.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. Insights platforms
    • 5.6.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.3. API/embedded models
    • 5.6.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Pricing Benchmarks and ACV Ranges (2025)

• 6.1. Buyer X Product Type ACV Benchmarks
  • 6.1.1. Pharmaceutical Companies
    • 6.1.1.1. Clinical Trial Enablement
      • 6.1.1.1.1. Data subscription (clinical + claims + quality datasets)
      • 6.1.1.1.2. Insights service (trial feasibility analytics)
      • 6.1.1.1.3. Model/engines (site selection AI tools)
    • 6.1.1.2. Health Systems & Providers
      • 6.1.1.2.1. Data (HCP-level claims + quality signals)
      • 6.1.1.2.2. Insights (targeting analytics)
      • 6.1.1.2.3. Models (real-time targeting engines)
    • 6.1.1.3. Safety, Adherence & HEOR
      • 6.1.1.3.1. Data (payer + quality + reimbursement datasets)
      • 6.1.1.3.2. Insights (access analytics)
      • 6.1.1.3.3. Models (pricing / access optimization tools)
    • 6.1.1.4. Formulary Analytics/Commercial Access Enablement
      • 6.1.1.4.1. Data (payer + quality + reimbursement datasets)
      • 6.1.1.4.2. Insights (access analytics)
      • 6.1.1.4.3. Models (pricing / access optimization tools)
  • 6.1.2. Health Systems & Providers
    • 6.1.2.1. Data (EMR + claims + quality data)
    • 6.1.2.2. Insights (care gap + operational analytics)
    • 6.1.2.3. Models (VBC optimization engines)
  • 6.1.3. Retail Pharmacies
    • 6.1.3.1. Data (patient + prescription + adherence signals)
    • 6.1.3.2. Insights (patient behavior / refill optimization)
    • 6.1.3.3. Models (adherence / engagement engines)
  • 6.1.4. Other Non-Payer Healthcare Entities
    • 6.1.4.1. Data packages
    • 6.1.4.2. Insights platforms
    • 6.1.4.3. API / embedded models
• 6.2. By Contract Structure
  • 6.2.1. Annual license
  • 6.2.2. Per-query / API-based
  • 6.2.3. Subscription vs bulk licensing
• 6.3. Cross-Cutting Pricing Questions & Premium Drivers

Chapter 7. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer Demand & WTP Ranking

• 7.1. Ranking by Buyer & Product Type Segment
  • 7.1.1. Willingness to Pay (WTP) Analysis Anchors
• 7.2. Observable Demand Signals
  • 7.2.1. Published or disclosed contract values
  • 7.2.2. Request for proposal (RFP) trends
  • 7.2.3. Transaction comps for comparable payer-adjacent data assets
• 7.3. Adoption Benchmarks
  • 7.3.1. Average sales cycle length by buyer segment
  • 7.3.2. Time-to-first-deal for comparable new entrants
  • 7.3.3. Product-type adoption rates

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Profiles/Listing
  • 8.2.1. Arcadia Solutions, LLC
    • 8.2.1.1. Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Inovalon
    • 8.2.2.1. Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. IQVIA
    • 8.2.3.1. Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Optum, Inc.
    • 8.2.4.1. Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Komodo Health, Inc.
    • 8.2.5.1. Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Cotiviti, Inc.
    • 8.2.6.1. Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Symphony Health
    • 8.2.7.1. Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. Definitive Healthcare
    • 8.2.8.1. Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Truveta
    • 8.2.9.1. Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product Benchmarking
    • 8.2.9.4. Strategic Initiatives
• 8.3. Monetization Models Overview
  • 8.3.1.1. Assessment across data, insights, and model-driven offerings
  • 8.3.1.2. Directional view of pricing approaches and commercialization model
  • 8.3.1.3. Pricing Mechanism Taxonomy
  • 8.3.1.4. Company-Level Commercialization Model Summary
  • 8.3.1.5. Directional ACV Benchmarking Summary
  • 8.3.1.6. Key Commercial Dynamics & Implications